8-K 1 ctdh20200505_8k.htm FORM 8-K ctdh20200505_8k.htm


Washington, D.C. 20549




Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934



Date of Report (Date of earliest event reported)      May 4, 2020          


(Exact name of registrant as specified in charter)


Florida   000-25466   59-3029743
(State or other Jurisdiction of Incorporation or Organization)   (Commission File Number)   (IRS Employer Identification No.)



6714 NW 16th Street, Suite B, Gainesville, Florida 



  (Address of Principal Executive Offices) (zip code)  



(Registrant’s telephone
number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:


☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐   Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))


☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

Trading Symbol(s)

Name of each exchange on which registered





Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).


Emerging growth company ☐                


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 




Item 1.01 Entry into a Material Definitive Agreement

On May 4, 2020, Cyclodextrin Technologies Development, Inc., a wholly-owned subsidiary of Cyclo Therapeutics, Inc. (the “Company”), borrowed $158,524 from BBVA USA under the Paycheck Protection Program which was established under the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”). The loan matures on May 4, 2022 and bears interest at a rate of 1% per annum, payable monthly commencing on December 4, 2020. Under the Paycheck Protection Program, the loan may be partially or wholly forgiven if the loan is used to fund certain qualifying expenses as described in the CARES Act. The Company intends to use all of the loan proceeds for qualifying expenses and to apply for forgiveness of the loan in accordance with the terms of the CARES Act.


Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant


The information contained in Item 1.01 above is hereby incorporated by reference into this Item 2.03. Upon a default under the Promissory Note evidencing the loan, including the non-payment of principal or interest, the obligations of the borrower under the Promissory Note may be accelerated.


Item 9.01. Financial Statements and Exhibits.


(d)       Exhibits.    


Exhibit No.  Description of Exhibit


Promissory Note dated May 4, 2020, by Cyclodextrin Technologies Development, Inc. in favor of BBVA USA.






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Cyclo Therapeutics, Inc.


Date: May 6, 2020


By: /s/ Joshua M. Fine                 

Joshua M. Fine

Chief Financial Officer